Ex-Genzyme chief Termeer joins board at Cambridge biotech

Moderna Therapeutics has scored another coup. The biotech, which struck a major development deal with AstraZeneca ($AZN) just months after it shed stealth status, has landed former Genzyme CEO Henri Termeer for the board of directors. Report

Suggested Articles

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.